Biotech Co.* (Country; Symbol) Pharma Co. (Country) Type/Product Area Terms/Details (Date)
Access Pharmaceuticals Inc. (AMEX:AKC) SpePharm Holding BV (the Netherlands) Definitive licensing agreement under which SpePharm will market Access's product MuGard in Europe for oral mucositis SpePharm will market the product in the European Union, plus Switzerland, Norway and Iceland, and it will manufacture the product and obtain regulatory approvals; it will pay Access an up-front fee and sub-stantial royalties on net sales (8/27)
ALK-Abello A/S (Denmark; CSE:ALK-B) Catalent Pharma Solutions Inc. Agreement to enable an increase in Zydis oral dissolving tablet production capacity dedicated to ALK-Abello's immunotherapy products ALK-Abello will fund a new production line for current and future tablet-based allergy products, which will be based at Catalent's Swindon, UK facility (9/5)**
A-Bio Pharma Pte. Ltd.* (Singapore) Artisan Pharma Inc. Manufacturing agreement for ART-123, a recombinant protein for the treatment of disseminated intravascular coagulation in sepsis A-Bio will undertake development and validation activities, and Artisan will enter into a preferential and long-term supply agreement (9/18)
Anesiva Inc. (ANSV) Sagent Pharmaceuticals Partnership to co-promote Zingo to reduce pain associated with peripheral venous access procedures Zingo was approved by the FDA in August for use in children ages 3 to 18 (10/12)
Anesiva Inc. (ANSV) Wanbang Pharmaceuticals (China) Joint manufacturing venture to expand worldwide production capacity for Zingo Anesiva will own 49% of the joint venture, which will be named Wanbang/Anesiva Pharmaceuticals Ltd. (10/12)
Ceremed Inc.* Nycomed Denmark A/S(Demark) Licensing agreement for distribution rights to the synthetic bone hemostasis material Ostene from Ceremed The product is designed to stop bone bleeding in surgery that does not interfere with bone healing or increase the risk of surgical infections (10/24)
Eden Biodesign Ltd. (UK; EDEN) Borean Pharma ApS (Denmark) Agreement for Eden to manufacture MBP-DC-SIGN, a candidate in cancer, for Borean's preclinical studies Financial terms were not disclosed (9/10)
Generex Biotechnology Corp. (GNBT) care Ltd. (South Africa) Adcock Ingram Ltd. and Adcock Ingram Health-and sale of Generex Oral-lyn Product licensing and distribution agreement for the marketing, distribution The agreement is for South Africa, Lesotho, Swaziland, Botswana, Namibia, Mozambique and Zimbabwe (10/19)
Helix BioMedix (OTC BB:HXBM) Degussa Goldschmidt Personal Care Agreement to exclusively market the Combikine and Replikine class of anti-aging peptides The agreement also includes other selected peptides targeted at skin care applications (9/5)
ImmunoGen Inc. (IMGN) Laureate Pharma Inc. Contract manufacturing agreement for the huC242 antibody used in the production of the company's huC242-DMA tumor-activated prodrug compound, which is in Phase II testing Terms of the agreement were not disclosed (11/1)
Meditrina Pharmaceuticals Inc.* Pfizer Inc. Contract manufacturing agreement for Femathina (MPI-674) with a unit of Pfizer CentreSource MPI-674 is an aromatase inhibitor in Phase II development that Meditrina is repurposing for the treatment of women's health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding; terms were not disclosed (9/19)
Nanobac Pharmaceuticals Inc. (OTC BB:NNBP) American Health Associates Clinical Laboratories Agreement for American Health to serve as the exclusive U.S. provider of Nanobac tests that can detect blood levels of calcifying nanoparticles Nanobac's laboratory in Finland will continue to service the world market (9/12)
Orexo AB (Sweden; SSE:ORX) Hospira Agreement giving Hospira exclusive marketing and selling rights to Rapinyl for breakthrough cancer pain Hospira will market the drug in Australia, New Zealand and other Asian Pacific areas (10/25)
Salix Pharmaceuticals (SLXP) Catalent Pharma Solutions Agreement to supply metoclopramide-Zydis Catalent's Zydis technology is a freeze-dried oral solid dosage form that disintegrates rapidly on the tongue and can be taken without water (9/5)
Salix Pharmaceuticals (SLXP) Mayoly-Spindler SAS (France) Licensing agreement for exclusive rights to market Osmoprep tablets in France Salix may receive up to $1M in milestone payments as well as royalties (10/4)
Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange.